71 related articles for article (PubMed ID: 1961692)
1. Light-dark phase differences in behavioral effects of moclobemide in rats.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1991; 43(3):177-86. PubMed ID: 1961692
[TBL] [Abstract][Full Text] [Related]
2. Some central effects of brofaromine given repeatedly are phase-dependent.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1990; 42(4):313-20. PubMed ID: 2097592
[TBL] [Abstract][Full Text] [Related]
3. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats.
Zajaczkowski W; Górka Z
Pol J Pharmacol; 1993; 45(2):157-66. PubMed ID: 8401768
[TBL] [Abstract][Full Text] [Related]
4. Effects of repeated treatment with antidepressant drugs on the 24 hour behavior in the light-dark synchronized mice.
Górka Z; Maj J
Pol J Pharmacol Pharm; 1986; 38(5-6):493-9. PubMed ID: 3575167
[TBL] [Abstract][Full Text] [Related]
5. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming.
Ferigolo M; Barros HM; Marquardt AR; Tannhauser M
Pharmacol Biochem Behav; 1998 Jun; 60(2):431-7. PubMed ID: 9632226
[TBL] [Abstract][Full Text] [Related]
6. The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze.
Eroğlu L; Güven O
Pharmacol Res; 1998 Feb; 37(2):137-43. PubMed ID: 9572069
[TBL] [Abstract][Full Text] [Related]
7. The rate of behavioral tolerance development to repeated lipopolysaccharide treatments depends upon the time of injection during the light-dark cycle: a multivariable examination of locomotor activity.
Franklin AE; Engeland CG; Kavaliers M; Ossenkopp KP
Behav Brain Res; 2007 Jun; 180(2):161-73. PubMed ID: 17433456
[TBL] [Abstract][Full Text] [Related]
8. Anxiolytic and memory improving effects of moclobemide.
Nowakowska E; Chodera A; Kus K; Rybakowski J
Arzneimittelforschung; 1998 Jun; 48(6):625-8. PubMed ID: 9689417
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
10. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide.
Mori S; Zanardi R; Popoli M; Garbini S; Brunello N; Smeraldi E; Racagni G; Perez J
J Psychiatr Res; 1998; 32(2):111-5. PubMed ID: 9694007
[TBL] [Abstract][Full Text] [Related]
11. An activity indicator of acute withdrawal depends on amphetamine dose in rats.
White W; White IM
Physiol Behav; 2006 Feb; 87(2):368-76. PubMed ID: 16364380
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
13. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
Juruena MF; Pires ML; Calil HM
Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent effects of antidepressant drugs on the low dose of apomorphine-induced locomotor hypoactivity in rats.
Dziedzicka-Wasylewska M; Rogóz Z
Pol J Pharmacol; 1997; 49(5):337-43. PubMed ID: 9566033
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of alcohol consumption and withdrawal on circadian temperature and activity rhythms in Sprague-Dawley, Lewis, and Fischer male and female rats.
Taylor AN; Tio DL; Bando JK; Romeo HE; Prolo P
Alcohol Clin Exp Res; 2006 Mar; 30(3):438-47. PubMed ID: 16499484
[TBL] [Abstract][Full Text] [Related]
16. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
[TBL] [Abstract][Full Text] [Related]
18. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
[TBL] [Abstract][Full Text] [Related]
19. [The effect of pyrazidol and inkazan on the rotation behavior of rats].
Mashkovskiĭ MD; Bogdanov MB; Bondarenko NA
Farmakol Toksikol; 1989; 52(6):29-32. PubMed ID: 2625142
[TBL] [Abstract][Full Text] [Related]
20. The effect of scheduled forced wheel activity on body weight in male F344 rats undergoing chronic circadian desynchronization.
Tsai LL; Tsai YC
Int J Obes (Lond); 2007 Sep; 31(9):1368-77. PubMed ID: 17356527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
